The business performance of the Company during the quarter ended 31st December, 2019 showed a marked improvement with Sales growth of over 8% compared to previous quarter.EBITDA for the quarter showed a substantial improvement from Rs.19 crore in Q3FY19 to Rs.109 Crore in Q3FY20. 9MFY20 EBITDA also showed an improvement from Rs. 100 crore to Rs.208 crore over previous year.

The Company has been reporting steady EBITDA Quarter by Quarter, for the first time in the past 3 years, the Company bounces back into Profit (PAT OF Rs 9 crore) owing to markedimprovement in Operational Performance & Cost rationalisation.Sales during Q3FY20 were at Rs. 869 crore, lower by 17% as compared to corresponding quarter
of previous year.

The focus in strategic R&D initiatives of the Company in the global arena continued to remain one of the key priorities. Such strategic R&D expenses though meant for the future are expensed off.

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt’s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes – 2 of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”. It also has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt  employs over 7000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 72% of its global revenues coming from international busines